Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Thiobenzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.55 |
| ▸ | CA4 known ✓ | P22748 | 2/20 | 0.55 |
| ▸ | CA12 known ✓ | O43570 | 2/20 | 0.50 |
| ▸ | CA1 known ✓ | P00915 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 5/20 | 0.55 |
| ▸ | CES2 | O00748 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | DAO | P14920 | 1/20 | 0.55 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiobenzoic Acid SCHEMBL3343877 | 1.00 | CES1 (0.55) | CES1CES2TSHRALDH1A1DAO | |
| Thiobenzoic Acid SCHEMBL6768672 | 0.94 | CES1 (0.55) | CES1CES2TSHRALDH1A1DAO | |
| Thiobenzoic Acid SCHEMBL11322369 | 0.94 | CES1 (0.55) | CES1CES2TSHRALDH1A1DAO | |
| Thiobenzoic Acid SCHEMBL26983522 | 0.94 | CES1 (0.55) | CES1CES2TSHRALDH1A1DAO | |
| Thiobenzoic Acid SCHEMBL6890936 | 0.94 | CES1 (0.55) | CES1CES2TSHRALDH1A1DAO | |
| Thiobenzoic Acid SCHEMBL284147 | 0.94 | CES1 (0.55) | CES1CES2TSHRALDH1A1DAO | |
| Thiobenzoic Acid SCHEMBL7898028 | 0.94 | CES1 (0.55) | CES1CES2TSHRALDH1A1DAO | |
| Thiobenzoic Acid SCHEMBL20741483 | 0.94 | CES1 (0.55) | CES1CES2TSHRALDH1A1DAO | |
| Thiobenzoic Acid SCHEMBL22721210 | 0.94 | CES1 (0.55) | CES1CES2TSHRALDH1A1DAO | |
| Thiobenzoic Acid SCHEMBL10405316 | 0.94 | CES1 (0.55) | CES1CES2TSHRALDH1A1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119326944-A | Wound healing-promoting antibacterial hydrogel wound dressing with hydrogen sulfide as self-supply and preparation method and application thereof | 西北工业大学 | 2025-01-21 | — | — | CN | claimed |
| CN-116322656-A | Oral treatment of Prevotella denticola strain C as an inflammatory disease | 伊夫罗生物科学公司 | 2023-06-23 | — | — | CN | claimed |
| CN-114009400-A | Anti-tumor experimental animal model and construction method thereof | 南京平港信息技术有限公司 | 2022-02-08 | — | — | CN | claimed |
| CN-110724209-B | Fucosylated chondroitin sulfate oligosaccharide and preparation method, composition and application thereof | 烟台东诚药业集团股份有限公司 | 2021-11-19 | — | — | CN | claimed |
| CN-110724209-A | Fucosylated chondroitin sulfate oligosaccharide and preparation method, composition and application thereof | 北京大学 | 2020-01-24 | — | — | CN | claimed |
| EP-0197407-A2 | Process for the preparation of 1,2-dithiolan-3-pentanoic acid (thioctic acid) | ASTA Pharma Aktiengesellschaft (DE) | 1986-10-15 | — | — | EP | claimed |
| CN-122036574-A | Drug design strategy for releasing hydrogen sulfide based on enzymolysis thiocarbonyl and application of drug design strategy in modification of terminal carboxylic acid drug | 中国药科大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-122036573-A | Drug design strategy for releasing hydrogen sulfide based on enzymolysis thiocarbonyl and application of drug design strategy in diclofenac-like drug modification | 中国药科大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-122036588-A | Drug design strategy for releasing hydrogen sulfide based on enzymolysis thiocarbonyl and application of drug design strategy in indole mother nucleus drug modification | 中国药科大学 | 2026-05-15 | — | — | CN | disclosed |
| US-12421270-B2 | Oligosaccharide, preparation method therefor, composition thereof and use thereof | Yantai Dongcheng Biochemicals Co., Ltd (CN) | 2025-09-23 | — | — | US | disclosed |
| CN-119490441-A | Prodrug design strategy for releasing hydrogen sulfide based on direct esterase hydrolysis thiocarboxylic acid and application of prodrug design strategy in modification of carboxylic acid drugs | 中国药科大学 | 2025-02-21 | — | — | CN | disclosed |
| CN-119326944-A | Wound healing-promoting antibacterial hydrogel wound dressing with hydrogen sulfide as self-supply and preparation method and application thereof | 西北工业大学 | 2025-01-21 | — | — | CN | disclosed |
| CN-117924393-A | Monomer of 3' -mercapto nucleoside analogue and its synthesis process | 天津兴博润生物制药有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-4098884-A | ANTITUMOR AGENTS | SOCIETA' FARMACEUTICI ITALIA S.P.A. (IT) | 1978-07-04 | — | — | US | disclosed |
| US-4083989-A | MORPHOGENETIC HORMONAL MIMETIC ACTIVITY | CHEVRON RESEARCH COMPANY (US) | 1978-04-11 | — | — | US | disclosed |
| US-4053470-A | BACTERICIDES, ANTIBIOTICS | PARKE, DAVIS & COMPANY (US) | 1977-10-11 | — | — | US | disclosed |
| US-4039536-A | 7-(α-SUBSTITUTED GLYCINAMIDO)-3-SUBSTITUTED METHYL-3-CEPHEM-4-CARBOXYLIC ACIDS AND THEIR DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1977-08-02 | — | — | US | disclosed |
| US-4024249-A | FOR COMBATTING MICROORGANISMS | CIBA-GEIGY CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-3988471-A | Insect control employing certain benzoates | CHEVRON RESEARCH COMPANY (US) | 1976-10-26 | — | — | US | disclosed |
| US-3954734-A | PENICILLIN AND CEPHALOSPORIN TYPE | PARKE, DAVIS & COMPANY | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421270-B2 | Oligosaccharide, preparation method therefor, composition thereof and use thereof | ALG1, FUCA1, FUT8 | CA2 1590/4885CA4 345/4885CA12 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.